Daniel Grant Clark - 30 Sep 2021 Form 3 Insider Report for Kiromic Biopharma, Inc. (KRBPQ)

Role: Interim CFO
Signature: /s/ Daniel Grant Clark
Issuer symbol: KRBPQ
Transactions as of: 30 Sep 2021
Net transactions value: $0
Form type: 3
Filing time: 14 Oct 2021, 18:24:05 UTC
Next filing: 15 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	KRBP	Common Stock						6,866	30 Sep 2021	Direct
holding	KRBP	Restricted Stock Units						29,516	30 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KRBP	Stock Option (right to buy)							30 Sep 2021	Common Stock	5,152	$17.47	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported restricted stock units will be settled in an equal number of shares of common stock, and vest according to the same schedule: 20% of the restricted stock units vested on June 30, 2021, and 20% of the restricted stock units will vest on each of (i) June 30, 2022, (ii) June 30, 2023, (iii) June 30, 2024, and (iv) June 30, 2025.
F2	The original number of shares subject to the stock option was 18,000, and the initial exercise price was $5.00. The Company underwent a 1-for-3.494 reverse stock split which adjusted the amount of shares subject to the option and the exercise price accordingly. Subject to continuing employment, the stock option vested with respect to 572 shares on June 8, 2020, with the remaining shares vesting at a rate of 1/32 per month for the next 32 months. As of the filing this report, 2,862 shares have vested and 2,290 shares remain unvested.

Content

The reported restricted stock units will be settled in an equal number of shares of common stock, and vest according to the same schedule: 20% of the restricted stock units vested on June 30, 2021, and 20% of the restricted stock units will vest on each of (i) June 30, 2022, (ii) June 30, 2023, (iii) June 30, 2024, and (iv) June 30, 2025.

The original number of shares subject to the stock option was 18,000, and the initial exercise price was $5.00. The Company underwent a 1-for-3.494 reverse stock split which adjusted the amount of shares subject to the option and the exercise price accordingly. Subject to continuing employment, the stock option vested with respect to 572 shares on June 8, 2020, with the remaining shares vesting at a rate of 1/32 per month for the next 32 months. As of the filing this report, 2,862 shares have vested and 2,290 shares remain unvested.